

# Lynn Morris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3275023/publications.pdf>

Version: 2024-02-01

148  
papers

14,475  
citations

25423

59  
h-index

22488

117  
g-index

149  
all docs

149  
docs citations

149  
times ranked

11384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. <i>Nature Communications</i> , 2022, 13, 903.	5.8	7
2	Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. <i>Viruses</i> , 2021, 13, 397.	1.5	1
3	Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. <i>Viruses</i> , 2021, 13, 1296.	1.5	3
4	mRNA vaccines offer hope for HIV. <i>Nature Medicine</i> , 2021, 27, 2082-2084.	15.2	9
5	Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. <i>Journal of Virology</i> , 2020, 94, .	1.5	15
6	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet, The</i> , 2020, 395, 384-388.	6.3	44
7	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. <i>PLoS ONE</i> , 2020, 15, e0234937.	1.1	3
8	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
9	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020, 31, 107488.	2.9	53
10	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
11	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
12	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
13	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
14	Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAbs lineage. <i>PLoS Pathogens</i> , 2019, 15, e1008005.	2.1	6
15	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	3.2	51
16	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. <i>Cell</i> , 2019, 179, 1636-1646.e15.	18.5	219
17	Engineered HIV antibody passes muster. <i>Lancet HIV</i> , 2019, 6, e641-e642.	2.1	1
18	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. <i>Journal of Virology</i> , 2019, 93, .	1.5	13

#	ARTICLE	IF	CITATIONS
19	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018, 25, 3123-3135.e6.	2.9	23
20	Measuring the ability of HIV-specific antibodies to mediate trogocytosis. <i>Journal of Immunological Methods</i> , 2018, 463, 71-83.	0.6	32
21	HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. <i>Journal of Virology</i> , 2018, 92, .	1.5	47
22	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. <i>Cell Host and Microbe</i> , 2018, 23, 845-854.e6.	5.1	100
23	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. <i>Aids</i> , 2017, 31, 2199-2209.	1.0	13
24	Prospects for passive immunity to prevent HIV infection. <i>PLoS Medicine</i> , 2017, 14, e1002436.	3.9	29
25	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017, 13, e1006074.	2.1	33
26	Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. <i>Science Translational Medicine</i> , 2016, 8, 358ra125.	5.8	121
27	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	2.7	34
28	Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2248-2256.	1.4	17
29	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	2.9	45
30	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	1.5	205
31	HIV broadly neutralizing antibody targets. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 135-143.	1.5	110
32	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on I±4I±7 for replication. <i>Retrovirology</i> , 2015, 12, 54.	0.9	19
33	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. <i>PLoS ONE</i> , 2015, 10, e0131906.	1.1	26
34	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 55-61.	0.9	10
35	Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 803-809.	4.6	47
36	Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 776-782.	0.5	14

#	ARTICLE	IF	CITATIONS
37	Virological features associated with the development of broadly neutralizing antibodies to HIV-1. <i>Trends in Microbiology</i> , 2015, 23, 204-211.	3.5	77
38	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	3.9	188
39	Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nucleoside Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 960-971.	1.4	48
40	Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 463-471.	0.9	14
41	Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. <i>Journal of Immunology</i> , 2015, 194, 4371-4378.	0.4	85
42	The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. <i>Journal of Virological Methods</i> , 2015, 223, 30-32.	1.0	8
43	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015, 21, 1332-1336.	15.2	215
44	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
45	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. <i>Journal of Infectious Diseases</i> , 2015, 211, 1461-1466.	1.9	7
46	Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. <i>Journal of Infectious Diseases</i> , 2014, 209, 711-720.	1.9	47
47	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A20-A21.	0.5	1
48	The Sequence of the $\hat{1}\pm 4\hat{1}^{27}$ -binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A56-A56.	0.5	1
49	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681
50	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	5.1	137
51	Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. <i>Journal of Virological Methods</i> , 2014, 207, 182-187.	1.0	5
52	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. <i>Cell Host and Microbe</i> , 2014, 16, 215-226.	5.1	105
53	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	13.7	702
54	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. <i>Infection, Genetics and Evolution</i> , 2013, 18, 125-131.	1.0	58

#	ARTICLE	IF	CITATIONS
55	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. <i>PLoS Pathogens</i> , 2013, 9, e1003738.	2.1	190
56	The Antibody Response against HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007039-a007039.	2.9	152
57	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. <i>Virology</i> , 2012, 433, 410-420.	1.1	12
58	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. <i>Journal of Experimental Medicine</i> , 2012, 209, 1469-1479.	4.2	156
59	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. <i>PLoS ONE</i> , 2012, 7, e36438.	1.1	63
60	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 <sup>+</sup> T Cell Decline and High Viral Load during Acute Infection. <i>Journal of Virology</i> , 2011, 85, 4828-4840.	1.5	441
61	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. <i>Journal of Virology</i> , 2011, 85, 3128-3141.	1.5	151
62	Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 Infection. <i>PLoS ONE</i> , 2011, 6, e21450.	1.1	8
63	Extreme Genetic Divergence Is Required for Coreceptor Switching in HIV-1 Subtype C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 9-15.	0.9	38
64	HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. <i>Aids</i> , 2011, 25, 1461-1469.	1.0	39
65	Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. <i>BMC Public Health</i> , 2011, 11, 88.	1.2	69
66	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. <i>Journal of Virology</i> , 2011, 85, 7719-7729.	1.5	54
67	Detection of Low-Level K65R Variants in Nucleoside Reverse Transcriptase Inhibitor-“Naive Chronic and Acute HIV-1 Subtype C Infections. <i>Journal of Infectious Diseases</i> , 2011, 203, 798-802.	1.9	26
68	Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa. <i>PLoS ONE</i> , 2011, 6, e17518.	1.1	84
69	Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa. <i>Journal of AIDS &amp; Clinical Research</i> , 2011, 02, .	0.5	30
70	Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. <i>Journal of Virological Methods</i> , 2010, 164, 122-126.	1.0	16
71	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. <i>Virology</i> , 2010, 402, 187-196.	1.1	95
72	Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor-“Based Viral Suppression. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1082.	3.8	75

#	ARTICLE	IF	CITATIONS
73	Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. <i>Aids</i> , 2010, 24, 1679-1687.	1.0	100
74	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. <i>Science</i> , 2010, 329, 1168-1174.	6.0	2,239
75	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. <i>PLoS ONE</i> , 2009, 4, e4505.	1.1	109
76	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. <i>Journal of Virology</i> , 2009, 83, 8925-8937.	1.5	170
77	Persistent Minority K103N Mutations among Women Exposed to Single-Dose Nevirapine and Virologic Response to Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy. <i>Clinical Infectious Diseases</i> , 2009, 48, 462-472.	2.9	74
78	Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 49, 1928-1935.	2.9	107
79	Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. <i>Aids</i> , 2009, 23, 809-816.	1.0	17
80	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. <i>PLoS Pathogens</i> , 2009, 5, e1000598.	2.1	213
81	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. <i>Journal of Virology</i> , 2009, 83, 1240-1259.	1.5	67
82	Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3056-3064.	1.4	16
83	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. <i>Journal of Virology</i> , 2009, 83, 11265-11274.	1.5	93
84	Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. <i>Journal of Virology</i> , 2009, 83, 470-478.	1.5	63
85	Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. <i>Virology</i> , 2009, 385, 505-520.	1.1	78
86	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. <i>Virology</i> , 2009, 387, 414-426.	1.1	86
87	Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. <i>Virology</i> , 2009, 393, 56-67.	1.1	14
88	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. <i>Nature Medicine</i> , 2009, 15, 866-870.	15.2	390
89	Specificity of the autologous neutralizing antibody response. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 358-363.	1.5	59
90	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	1.5	548

#	ARTICLE	IF	CITATIONS
91	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. <i>Journal of Virology</i> , 2008, 82, 11651-11668.	1.5	337
92	Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study. <i>Journal of Virology</i> , 2008, 82, 11476-11479.	1.5	38
93	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. <i>Journal of Virology</i> , 2008, 82, 1860-1869.	1.5	142
94	4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response. <i>Journal of Virology</i> , 2008, 82, 2367-2375.	1.5	37
95	HIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1449-1454.	0.5	54
96	Development of Phenotypic HIV-1 Drug Resistance After Exposure to Single-Dose Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 538-543.	0.9	9
97	Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. <i>Aids</i> , 2008, 22, 1333-1343.	1.0	83
98	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. <i>PLoS ONE</i> , 2008, 3, e1954.	1.1	175
99	N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. <i>Journal of Virology</i> , 2007, 81, 10769-10776.	1.5	42
100	Polymorphisms in Nef Associated with Different Clinical Outcomes in HIV Type 1 Subtype C-Infected Children. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 204-215.	0.5	21
101	A Model of Directional Selection Applied to the Evolution of Drug Resistance in HIV-1. <i>Molecular Biology and Evolution</i> , 2007, 24, 1025-1031.	3.5	33
102	Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 316-321.	0.5	25
103	Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 169-176.	1.5	20
104	Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 148-153.	0.9	79
105	Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 206-209.	0.9	29
106	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. <i>Virology</i> , 2007, 368, 172-181.	1.1	45
107	HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. <i>Aids</i> , 2006, 20, 643-651.	1.0	78
108	Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. <i>Aids</i> , 2006, 20, 995-1002.	1.0	87

#	ARTICLE	IF	CITATIONS
109	Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. <i>Virology</i> , 2006, 356, 95-105.	1.1	59
110	High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. <i>Journal of Medical Virology</i> , 2006, 78, 1262-1268.	2.5	5
111	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. <i>Journal of Virology</i> , 2006, 80, 11776-11790.	1.5	334
112	Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 694-701.	1.4	78
113	Silencing of HIV-1 Subtype C Primary Isolates by Expressed Small Hairpin RNAs Targeted togag. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 401-410.	0.5	13
114	Resistance Mutational Analysis of HIV Type 1 Subtype C among Rural South African Drug-Naive Patients Prior to Large-Scale Availability of Antiretrovirals. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1306-1312.	0.5	32
115	Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 2515-2528.	1.5	309
116	Genotypic and Phenotypic Characterization of Viral Isolates from HIV-1 Subtype C-Infected Children with Slow and Rapid Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 458-465.	0.5	51
117	A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences. <i>Journal of Virology</i> , 2006, 80, 4698-4704.	1.5	124
118	Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. <i>PLoS Medicine</i> , 2006, 3, e255.	3.9	72
119	Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. <i>Journal of Virological Methods</i> , 2005, 125, 99-109.	1.0	10
120	Use of alternate coreceptors on primary cells by two HIV-1 isolates. <i>Virology</i> , 2005, 339, 136-144.	1.1	44
121	Emergence of Drug-Resistant HIV-1 after Intrapartum Administration of Single-Dose Nevirapine Is Substantially Underestimated. <i>Journal of Infectious Diseases</i> , 2005, 192, 16-23.	1.9	214
122	Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. <i>PLoS Medicine</i> , 2005, 2, e112.	3.9	262
123	Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. <i>Journal of Virology</i> , 2005, 79, 10103-10107.	1.5	233
124	Characterization of Human Immunodeficiency Virus Type 1 from a Previously Unexplored Region of South Africa with a High HIV Prevalence. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 103-109.	0.5	24
125	In Vitro Generation of HIV Type 1 Subtype C Isolates Resistant to Enfuvirtide. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 776-783.	0.5	14
126	Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. <i>Fertility and Sterility</i> , 2005, 84, 1001-1010.	0.5	50



#	ARTICLE	IF	CITATIONS
127	Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 285-291.	0.5	24
128	Incidence of HIV-1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIV-1 Subtype C-Infected Female Sex Workers. <i>Journal of Infectious Diseases</i> , 2004, 190, 1355-1359.	1.9	119
129	Does Tuberculosis Increase HIV Load?. <i>Journal of Infectious Diseases</i> , 2004, 190, 1677-1684.	1.9	71
130	Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. <i>Aids</i> , 2004, 18, 2327-2330.	1.0	14
131	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 133-144.	0.5	113
132	Human Immunodeficiency Virus-1 RNA Levels and CD4 Lymphocyte Counts, during Treatment for Active Tuberculosis, in South African Patients. <i>Journal of Infectious Diseases</i> , 2003, 187, 1967-1971.	1.9	68
133	Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. <i>Aids</i> , 2003, 17, 1698-1700.	1.0	27
134	HIV-1 Subtype C Reverse Transcriptase Sequences from Drug-Naive Pregnant Women in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 605-610.	0.5	38
135	HIV-1 Subtype A, D, G, AG and Unclassified Sequences Identified in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 681-683.	0.5	30
136	Full-Length Genome Analysis of HIV-1 Subtype C Utilizing CXCR4 and Intersubtype Recombinants Isolated in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 879-886.	0.5	39
137	Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. <i>Journal of Virology</i> , 2002, 76, 2233-2244.	1.5	111
138	Neutralizing Antibody Responses to HIV-1 Infection. <i>IUBMB Life</i> , 2002, 53, 197-199.	1.5	9
139	Conserved Domains of Subtype C Nef from South African HIV Type 1-Infected Individuals Include Cytotoxic T Lymphocyte Epitope-Rich Regions. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1681-1687.	0.5	20
140	Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140. <i>Journal of Virology</i> , 2001, 75, 579-588.	1.5	216
141	Characterization of Full-Length HIV Type 1 Subtype C Sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1527-1531.	0.5	52
142	AIDS dissidents aren't victims " but the people their ideas kill will be. <i>Nature</i> , 2000, 405, 273-273.	18.7	0
143	Identification of HIV Type 1 Intersubtype Recombinants in South Africa Using env and gag Heteroduplex Mobility Assays. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 493-497.	0.5	20
144	Meningitis in a community with a high prevalence of tuberculosis and HIV infection. <i>Journal of the Neurological Sciences</i> , 1999, 162, 20-26.	0.3	41

#	ARTICLE	IF	CITATIONS
145	The importance of doing HIV research in developing countries. <i>Nature Medicine</i> , 1998, 4, 1228-1229.	15.2	3
146	HIV-1 Antigen-specific and -nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy. <i>Journal of Experimental Medicine</i> , 1998, 188, 233-245.	4.2	234
147	Viral structure, replication, tropism, pathogenesis and natural history. , 0, , 87-96.		0
148	HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 0, , .	1.5	0